VIVA Friends Circle | ABM Therapeutics and Mosaica Medicines Sign Global Licensing Agreement for MEK Inhibitor ABM-168

San Diego, USA / Shanghai, China / – January 14, 2026 —— ABM Therapeutics, incubated and invested in by Viva Biotech, announced today,The company has entered into a global licensing and collaboration agreement with Boston-based biotechnology company Mosaica Medicines for its self-developed MEK1/2 inhibitor, ABM-168.Under the terms of the agreement, ABM Therapeutics will receive an upfront payment and is eligible for subsequent development, regulatory, and sales milestone payments.

ABM-168 is a highly potent allosteric MEK1/2 inhibitor that has demonstrated significant anti-tumor activity in various preclinical animal models, whether used as a single agent or in combination with other drugs. Preclinical studies also indicate that ABM-168 exhibits excellent blood-brain barrier penetration, effectively targeting brain metastatic cancer cells and malignant primary brain tumor cells.

In October 2022, ABM-168 received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) and has since initiated Phase I clinical trials (NCT05831995) across multiple oncology centers in the United States. In August 2023, ABM-168 also received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials in patients with advanced solid tumors, with a particular focus on patients with brain metastases and primary brain tumors. The study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity of ABM-168.

ABM-168 is a novel and highly potent allosteric MEK1/2 inhibitor designed to block oncogenic signaling pathways driven by RAS, RAF mutations, or signal amplification, thereby inhibiting tumor cell growth. In vivo studies have shown that ABM-168 demonstrates significant anti-tumor activity across various tumor models, whether used alone or in combination with other treatment regimens. These include orthotopic models of glioblastoma, intracranial and cardiac models of human melanoma, subcutaneous and orthotopic transplantation models of colorectal cancer, and pancreatic cancer tumor models. ABM-168 shows substantial proliferation inhibition in various tumor cell lines harboring RAS, RAF, and NF1 mutations and demonstrates excellent blood-brain barrier penetration.

ABM Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative small-molecule anti-cancer drugs, with an emphasis on therapies capable of penetrating the blood-brain barrier for treating brain metastases and central nervous system tumors. The company currently has multiple pipeline projects at different stages of development, aiming to address critical unmet clinical needs in the field of brain tumors and brain metastases.

Information related to incubated companies is provided by the incubated companies themselves and has not been independently verified by this company. Under no circumstances shall this company bear any direct or indirect liability (whether in tort, contractual liability, or otherwise) for losses or damages caused by inaccurate or omitted information in this press release or the use of such information.

Viva Biotech (01873.HK) was established in 2008, providing one-stop integrated services from early structure-based drug discovery to commercial drug production for innovative pharmaceutical companies worldwide. With a leading advantage in structure-based drug discovery (SBDD) technologies, we offer CRO services during the new drug research phase to global partners. Our advanced technology platforms include X-ray protein crystallography, cryo-electron microscopy (Cryo-EM), DNA-encoded library technology (DEL), affinity mass spectrometry screening (ASMS), surface plasmon resonance (SPR), hydrogen-deuterium exchange mass spectrometry (HDX-MS), AIDD/CADD, among others. We also have teams led by experienced medicinal chemists and drug discovery biology experts who provide services such as drug design, medicinal chemistry (H2L, LO), compound synthesis, chemical analysis and purification, kilogram-scale amplification, peptide synthesis, and corresponding bioactivity testing. Through our subsidiary Langhua Pharma, we provide one-stop CMC/CDMO solutions from preclinical development to commercial production. Furthermore, we focus on discovering and investing in high-potential biopharmaceutical startups, employing an equity-for-service (EFS) business model to address unmet clinical needs.